Informative, Innovative and Interactive Site of MP & Chhattisgarh
Un Site Informatif, Innovatif et Interactif de MP & Chhattisgarh

“It is not right in God’s sight to obey men rather than God.”

Weight-loss pills claim life of 30-year woman in Madhya Pradesh

BHOPAL: Overdose of pills allegedly taken for weight-loss claimed the life of a 30-year-old village woman in Chhindwara district of Madhya Pradesh.

The victim, Sita Nagwanshi, resident of Nolakhapa village, was admitted in the district hospital on Wednesday morning where she died after a few hours. Doctors attending the woman said she suffered a cardiac arrest.

Sita’s family said they were still clueless on the circumstances that led to her death and requested a probe.

However a doctor was informed by her husband that Sita was reeling under depression because of obesity and was consuming some unknown fat-burning pills for the last two weeks.

“Going by what her family told me, I am personally of the opinion that overdose of the unknown drug killed her,” said a health officer wishing anonymity.

Dr Narendra Hanote, who conducted post-mortem said detailed analysis was required to ascertain circumstances that led to her death. “I am not in a position of give any definite opinion now. Samples would be sent for forensic analysis,” he said.

There are several medical shops in Chhindwara and adjoining Nagpur in Maharashtra where such pills are being sold over the counter.

According to Indore based bariatric surgeon Dr Mohit Bhandari, "There have been several reports of death due to the so-called fat burning pills in the state. Drugs like Sibutramine suppress appetite and block the reuptake of neurotransmitters to trick the brain into thinking the stomach was full. They were extremely dangerous.”

He said placebos and steroids are being sold in the name of weight-loss drugs across the state.

In 2010, Drug Controller General of India (DCGI) had issued notices to all state drug controllers directing them to suspend licenses granted to manufacturers for sales, manufacturing and distribution of sibutramine, R-sibutramine and their formulations with immediate effect. The decision to stop manufacturing of the drug was taken in the wake of the studies suggesting higher risk of heart diseases from the use of this drug.